KAMAL M. BAKRI; LARRY P. WASSER
This content is PDF only. Please click on the PDF icon to access.
To the editor: We read with interest the article on prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia by Dekker and colleagues (1). We agree with the conclusion that more studies are needed before trimethoprim-sulfamethoxazole is used universally as a prophylactic antimicrobial drug in granulocytopenic patients (1-4). But we wonder if one more study like this, which does show a significant statistical difference favoring trimethoprim-sulfamethoxazole treatment to infection in granulocytopenic patients, adds anything to clear the existing confusion. Because this study, although randomized, had only a few patients in each group and also used
BAKRI KM, WASSER LP. Trimethoprim-Sulfamethoxazole and Granulocytopenia. Ann Intern Med. 1982;96:381–382. doi: https://doi.org/10.7326/0003-4819-96-3-381
Download citation file:
Published: Ann Intern Med. 1982;96(3):381-382.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use